Assessment of Quality of Life in Patients Under Go Neangioplasty and Takin Gticagrelor: A Prospective Observational Study
Main Article Content
Abstract
Acute Coronary Syndrome encompasses life threatening conditions including STEMI, NSTE, NSTEMI, and UA. Ticagrelor, an antiplatelet drug, reduces cardiac events but increases bleeding risk. DAPT with ticagrelor and aspirin is recommended post-PCI, with the duration determined by individual factors. Comprehensive prospective studies are essential to assess ticagrelor's real-world effectiveness and impact on patients' quality of life
References
https://www.heart.org/en/health-topics/heart-attack/about-heartattacks/acute-coronary-syndrome
Sanchis-Gomar F., Perez-Quilis C., Leischik R., Lucia A. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med. 2016 Jul; 4(13):256.
Overbaugh KJ. Acute coronary syndrome. Am J Nurs. 2009 May; 109(5):42–52; quiz 53.
Makki N., Brennan T.M., Girotra S. Acute coronary syndrome. J Intensive Care Med. 2015 May; 30(4):186–200.
https://my.clevelandclinic.org/health/diseases/22910-acute-coronary-syndrome
https://www.mayoclinic.org/diseases-conditions/acute-coronary-syndrome/symptoms-causes/syc-20352136
Sanchis-Gomar F., Perez-Quilis C., Leischik R., Lucia A. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med. 2016 Jul; 4(13):256.
Bhatt D.L. Percutaneous Coronary Intervention in 2018. JAMA. 2018 May 22; 319(20):2127–2128.
Khan S.Q., Ludman P.F. Percutaneous coronary intervention. Med. 2022 Jul 1; 50(7):437–444.
https://uh.edu/af/survival/P/PCIDataSecurityClassificationStandards.pdf
https://www.mayoclinic.org/tests-procedures/coronary-angioplasty/about/pac-20384761
https://www.sciencedirect.com/topics/medicine-and-dentistry/angioplasty
Astin F., Jones K., Thompson D.R. Prevalence and patterns of anxiety and depression in patients undergoing elective percutaneous transluminal coronary angioplasty. Heart Lung. 2005 Nov–Dec; 34(6):393–401.
Valappil S.P., Kunjukrishnapillai S., Iype M., et al. Predictors of contrast-induced nephropathy and applicability of Mehran risk score in high-risk patients undergoing coronary angioplasty. Indian Heart J. 2018 May–Jun; 70(3):399–404.
Passacquale G., Sharma P., Perera D., Ferro A. Antiplatelet therapy in cardiovascular disease: Current status and future directions. Br J Clin Pharmacol. 2022 Jun; 88(6):2686–2699.
https://www.heartandstroke.ca/heart-disease/treatments/medications/antiplatelet-medications
Parodi G., Storey R.F. Dyspnea management in acute coronary syndrome patients treated with ticagrelor. Eur Heart J Acute Cardiovasc Care. 2015 Dec; 4(6):555–560.
Danielak D., Karaźniewicz-Łada M., Główka F. Ticagrelor in modern cardiology – an up-to-date review. Expert Opin Pharmacother. 2018 Feb; 19(2):103–112.
Nawarskas J.J., Clark S.M. Ticagrelor: a novel reversible oral antiplatelet agent. Cardiol Rev. 2011 Mar–Apr; 19(2):95–100.
Tripathi K.D. Essentials of Medical Pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers; 2019.
Tomaniak M., Chichareon P., Onuma Y., et al. Benefit and risks of aspirin in addition to ticagrelor in acute coronary syndromes: Post hoc analysis of the GLOBAL LEADERS Trial. JAMA Cardiol. 2019 Nov 1; 4(11):1092–1101.
https://go.drugbank.com/drugs/DB08816
Andreou I., Briasoulis A., Pappas C., Ikonomidis I., Alexopoulos D. Ticagrelor versus clopidogrel as part of dual or triple antithrombotic therapy: A systematic review and meta-analysis. Cardiovasc Drugs Ther. 2018 Jun; 32(3):287–294.
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.